What is King Bio?
Founded 25 years ago by Dr. Frank King, King Bio has established itself as a cornerstone in the field of homeopathic and natural medicine. The company operates a robust portfolio of over 500 distinct medicines across six specialized brands, including the well-regarded SafeCareRx line. By integrating nearly 40 years of clinical experience into its manufacturing processes, King Bio provides essential condition-specific solutions to clinics nationwide. Beyond its proprietary product lines, the firm serves as a critical partner in the industry through its contract manufacturing and private label services, ensuring high-quality, safe, and natural therapeutic options remain accessible to a broad patient base.
How much funding has King Bio raised?
King Bio has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in King Bio
PPP
Public-Private Partnership
What's next for King Bio?
With this recent infusion of capital, King Bio is poised to accelerate its operational efficiency and broaden its reach within the integrative medicine market. The strategic focus will likely center on scaling production capacity to meet the rising demand for natural, evidence-based health solutions. By leveraging its established infrastructure and deep-rooted clinical trust, the company is set to enhance its private label offerings and potentially explore new therapeutic categories. This late-stage financing provides the necessary liquidity to solidify its competitive advantage, ensuring that King Bio remains at the forefront of the natural healthcare evolution while maintaining the rigorous safety standards that have defined its quarter-century legacy.
See full King Bio company page
